For the boys, prostate cancer screening is another case in
point. Screening is easy (just a blood test - a PSA) but like all screening programs
it is plagued by overdiagnosis, and the harms from treatment for this condition
are also quite significant (high rates of incontinence and erectile dysfunction).
The difference between this and breast cancer screening is
that there is less general acceptance, and more criticism from official
bodies and major academic
and popular
journals, and also from the guy who invented the PSA test in the first place (here).
The large scale randomised trials (the best evidence) on
this topic give conflicting results regarding the effectiveness, and again,
they concentrate on disease-specific mortality (which always makes screening
look better), rather than overall mortality.
For the best explanation of the relative risks and benefits
of PSA screening, read this
article from some excellent public health academics from Australia, who put
the risks and harms into numbers, to make it more digestible. They conclude:
“you have to screen 1408 men and
treat an additional 48 men to prevent one prostate cancer death over
9 years. In other words, only 1 of those 48 men is going to benefit
over the next 9 years; the other 47 … have undergone treatment for no
benefit within this period.”
No comments:
Post a Comment